These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 3749636)

  • 1. [The assessment of the arrhythmogenicity of a newly synthesized inotropic agent, TA-064 in clinical cases].
    Fukuda K; Handa S; Ohnishi S; Ogawa S; Yamazaki H; Nakamura Y
    Kokyu To Junkan; 1986 Jul; 34(7):783-9. PubMed ID: 3749636
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acute and chronic effects of oral cardiotonic agent, denopamine (TA-064) in patients with heart failure].
    Inden M; Yamamuro M; Murayama S; Noda E; Tanimura H; Takasaki H; Konishi T; Nakano T; Takezawa H
    Kokyu To Junkan; 1986 May; 34(5):541-6. PubMed ID: 3738247
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical studies with beta 2 adrenoceptor agonists in heart failure.
    Dawson JR; Bayliss J; Norell MS; Canepa-Anson R; Kuan P; Reuben S; Poole-Wilson PA; Sutton GC
    Eur Heart J; 1982 Dec; 3 Suppl D():135-41. PubMed ID: 6130947
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular effects of the new positive inotropic agent denopamine with special reference to species difference and the effect on failing heart.
    Ikeo T; Nagao T; Murata S; Yabana H; Sato M; Nakajima H
    Arzneimittelforschung; 1986 Jul; 36(7):1063-8. PubMed ID: 3768073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
    Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
    Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of a new inotropic agent--Prenalterol--in hypotension and heart failure.
    Reiz S; Waagstein F; Hjalmarson A
    Clin Cardiol; 1980 Apr; 3(2):96-105. PubMed ID: 6104553
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of TA-064 on bradyarrhythmias].
    Kobayashi Y; Nakamura M; Yazawa T; Baba T; Mukai H; Iwasaki S; Takeyama Y; Niitani H
    Kokyu To Junkan; 1986 Aug; 34(8):875-82. PubMed ID: 3786955
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute clinical benefits of a new inotropic agent AR-L 115 BS after i.v. and oral administration.
    el Allaf D; D'Orio V; Cremers S; Carlier J
    G Ital Cardiol; 1984 Oct; 14(10):830-4. PubMed ID: 6519393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
    Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient dobutamine-mediated pulsus alternans.
    Kahn JH; Starling MR; Supiano MA
    Can J Cardiol; 2001 Feb; 17(2):203-5. PubMed ID: 11223491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sulmazole: a new positive inotropic agent].
    Renard M; Jacobs P; Melot C; Dresse A; Bernard R
    Ann Cardiol Angeiol (Paris); 1984; 33(4):219-22. PubMed ID: 6465815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute hemodynamic effects of alifedrine in patients with heart failure].
    Schanzenbächer P; Riegger G; Liebau G; Hockerts T; Kochsiek K
    Z Kardiol; 1984 Feb; 73(2):95-100. PubMed ID: 6719988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemodynamic effects of the new inotropic agent sulmazol (AR-L115 BS) administered intravenously to patients with severe heart failure.
    Hagemeijer F; van Mechelen R; Schelling A
    Herz; 1983 Feb; 8(1):41-6. PubMed ID: 6832692
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of prenalterol in congestive heart failure.
    Hjalmarson A; Abelardo N; Waagstein E
    Eur Heart J; 1982 Dec; 3 Suppl D():115-21. PubMed ID: 7160397
    [No Abstract]   [Full Text] [Related]  

  • 15. [Acute and sustained hemodynamic effects of a new inotropic agent TA-064 (Denopamine) in patients with refractory heart failure with special reference to dose-response effects].
    Matsumoto N; Ito N; Kawagoe Y; Matsumura K; Honda T; Horie T; Takahashi S; Kimata S; Hirosawa K
    Kokyu To Junkan; 1986 Oct; 34(10):1113-20. PubMed ID: 3797842
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinicopharmacological studies of a newly synthesized cardiotonic agent (TA-064) in patients with congestive heart failure.
    Bito K; Kinoshita M; Mashiro I; Ozaki N; Sakoda S; Tsutamoto T; Motomura M; Mitsunami K; Fukuhara T; Kawakita S
    Clin Cardiol; 1988 May; 11(5):334-9. PubMed ID: 3383472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hemodynamic effect of AR-L 115 BS, a new positive-inotropic agent, in patients with left ventricular failure.
    Wollschläger H; Drexler H; Löllgen H; Just H
    Arzneimittelforschung; 1981; 31(1a):248-50. PubMed ID: 7195233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes.
    Gheorghiade M; Sabbah HN
    Am J Cardiol; 2007 Jan; 99(2A):1A-3A. PubMed ID: 17239700
    [No Abstract]   [Full Text] [Related]  

  • 19. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by beta-adrenergic blockade.
    Travill CM; Pugh S; Noble MI
    Clin Ther; 1994; 16(5):783-92. PubMed ID: 7859237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. If current inhibition and mortality reduction in heart failure: more than just a 'pure' effect of lowering heart rate.
    Musiałek P
    Kardiol Pol; 2013; 71(7):764-7. PubMed ID: 23907914
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.